241 related articles for article (PubMed ID: 30012674)
1. Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults.
Wang T; Hong JL; Gower EW; Pate V; Garg S; Buse JB; Stürmer T
Diabetes Care; 2018 Sep; 41(9):1998-2009. PubMed ID: 30012674
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults.
Wang T; Yang JY; Buse JB; Pate V; Tang H; Barnes EL; Sandler RS; Stürmer T
Diabetes Care; 2019 Nov; 42(11):2065-2074. PubMed ID: 31471377
[TBL] [Abstract][Full Text] [Related]
3. Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes.
Richardson TL; Halvorson AE; Hackstadt AJ; Hung AM; Greevy R; Grijalva CG; Elasy TA; Roumie CL
Ann Intern Med; 2023 Jun; 176(6):751-760. PubMed ID: 37155984
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study.
Gokhale M; Buse JB; Gray CL; Pate V; Marquis MA; Stürmer T
Diabetes Obes Metab; 2014 Dec; 16(12):1247-56. PubMed ID: 25109825
[TBL] [Abstract][Full Text] [Related]
5. Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes.
Yang JY; Moon AM; Kim H; Pate V; Barritt AS; Crowley MJ; Buse JB; Stürmer T; Alexopoulos AS
J Diabetes Complications; 2020 Nov; 34(11):107706. PubMed ID: 32843283
[TBL] [Abstract][Full Text] [Related]
6. No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternatives.
Gokhale M; Buse JB; Jonsson Funk M; Lund J; Pate V; Simpson RJ; Stürmer T
Diabetes Obes Metab; 2017 Jul; 19(7):970-978. PubMed ID: 28195389
[TBL] [Abstract][Full Text] [Related]
7. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
[TBL] [Abstract][Full Text] [Related]
8. Risk of Pancreatitis With Incretin Therapies Versus Thiazolidinediones in the Veterans Health Administration.
Wilhite K; Reid JM; Lane M
Ann Pharmacother; 2024 Jul; 58(7):685-689. PubMed ID: 37881914
[TBL] [Abstract][Full Text] [Related]
9. Glucose-Lowering Agents and the Risk of Hypoglycemia: a Real-world Study.
Lyu B; Hwang YJ; Selvin E; Jameson BC; Chang AR; Grams ME; Shin JI
J Gen Intern Med; 2023 Jan; 38(1):107-114. PubMed ID: 35831767
[TBL] [Abstract][Full Text] [Related]
10. Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors.
Htoo PT; Buse JB; Gokhale M; Marquis MA; Pate V; Stürmer T
Eur J Clin Pharmacol; 2016 Aug; 72(8):1013-23. PubMed ID: 27165664
[TBL] [Abstract][Full Text] [Related]
11. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study.
Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Juurlink DN; Targownik LE; Turin TC; Paterson JM; Ernst P;
BMJ; 2016 Feb; 352():i581. PubMed ID: 26888382
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data.
Ha KH; Kim B; Choi H; Kim DJ; Kim HC
Diabet Med; 2017 Sep; 34(9):1235-1243. PubMed ID: 28523719
[TBL] [Abstract][Full Text] [Related]
13. The Risk of Acute Pancreatitis After Initiation of Dipeptidyl Peptidase 4 Inhibitors: Testing a Hypothesis of Subgroup Differences in Older U.S. Adults.
Hong JL; Buse JB; Jonsson Funk M; Pate V; Stürmer T
Diabetes Care; 2018 Jun; 41(6):1196-1203. PubMed ID: 29618573
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users.
Gamble JM; Thomas JM; Twells LK; Midodzi WK; Majumdar SR
Medicine (Baltimore); 2016 Jun; 95(26):e3995. PubMed ID: 27368005
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
[TBL] [Abstract][Full Text] [Related]
16. Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study.
Ueda P; Wintzell V; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Svanström H; Pasternak B
Diabetologia; 2021 Oct; 64(10):2204-2214. PubMed ID: 34254177
[TBL] [Abstract][Full Text] [Related]
17. Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.
Garry EM; Buse JB; Lund JL; Pate V; Stürmer T
Diabetes Obes Metab; 2018 Jan; 20(1):129-140. PubMed ID: 28661561
[TBL] [Abstract][Full Text] [Related]
18. Sodium-Glucose Cotransporter 2 Inhibitors vs Incretin-Based Drugs and Risk of Fractures for Type 2 Diabetes.
Ko HY; Bea S; Jeong HE; Park S; Cho YM; Kong SH; Shin JY
JAMA Netw Open; 2023 Sep; 6(9):e2335797. PubMed ID: 37751205
[TBL] [Abstract][Full Text] [Related]
19. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study.
Abrahami D; Douros A; Yin H; Yu OH; Faillie JL; Montastruc F; Platt RW; Bouganim N; Azoulay L
BMJ; 2018 Dec; 363():k4880. PubMed ID: 30518618
[TBL] [Abstract][Full Text] [Related]
20. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
